ReviewBritish journal of pharmacology2012
Enhancing the utility of existing antibiotics by targeting bacterial behaviour?
Review in British journal of pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Quorum Sensing: Not Just a Bridge Between Bacteria.MicrobiologyOpen · 2025Review
- Combating biofilm-associated Klebsiella pneumoniae infections using a bovine microbial enzyme.NPJ biofilms and microbiomes · 2024Article
- Evaluation of the Effects of Heteroaryl Ethylene Molecules in Combination with Antibiotics: A Preliminary Study on Control Strains.Antibiotics (Basel, Switzerland) · 2023Article
- Antibiotic-free antimicrobial poly (methyl methacrylate) bone cements: A state-of-the-art review.World journal of orthopedics · 2022Review
- Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics.Antibiotics (Basel, Switzerland) · 2022Review
- Membrane-Active Antibacterial Agents Based on Calix[4]arene Derivatives: Synthesis and Biological Evaluation.Frontiers in chemistry · 2022Article
- Amixicile, a novel strategy for targeting oral anaerobic pathogens.Scientific reports · 2017Article
- Antibiofilm Activity and Synergistic Inhibition of Staphylococcus aureus Biofilms by Bactericidal Protein P128 in Combination with Antibiotics.Antimicrobial agents and chemotherapy · 2016Article
- The changing face of asthma and its relation with microbes.Trends in microbiology · 2015Review
- Bactericidal efficiency and modes of action of the novel antimicrobial peptide T9W against Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2015Article
- Antiadhesive activity of poly-hydroxy butyrate biopolymer from a marine Brevibacterium casei MSI04 against shrimp pathogenic vibrios.Microbial cell factories · 2014Article
- Survival of bactericidal antibiotic treatment by a persister subpopulation of Listeria monocytogenes.Applied and environmental microbiology · 2013Article
- Challenges and opportunities for faecal microbiota transplantation therapy.Epidemiology and infection · 2013Review
- Cystic fibrosis therapy: a community ecology perspective.American journal of respiratory cell and molecular biology · 2013Review
- Novel phytochemical-antibiotic conjugates as multitarget inhibitors of Pseudomononas aeruginosa GyrB/ParE and DHFR.Drug design, development and therapy · 2013Article
- Mechanisms of resistance in bacteria: an evolutionary approach.The open microbiology journal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of novel classes of antibiotics has slowed dramatically. This has occurred during a time when the appearance of resistant strains of bacteria has shown a substantial increase. Concern is therefore mounting over our ability to continue to treat infections in an effective manner using the antibiotics that are currently available. While ongoing efforts to discover new antibiotics are important, these must be coupled with strategies that aim to maintain as far as possible the spectrum of activity of existing antibiotics. In many instances, the resistance to antibiotics exhibited by bacteria in chronic infections is mediated not by direct resistance mechanisms, but by the adoption of modes of growth that confer reduced susceptibility. These include the formation of biofilms and the occurrence of subpopulations of 'persister' cells. As our understanding of these processes has increased, a number of new potential drug targets have been revealed. Here, advances in our ability to disrupt these systems that confer reduced susceptibility, and in turn increase the efficacy of antibiotic therapy, are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.